Citigroup’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-927,342
| Closed | -$12.1M | – | 5944 |
|
|
2025
Q4 | $12.1M | Buy |
927,342
+895,513
| +2,814% | +$10.7M | 0.01% | 1399 |
|
|
2025
Q3 | $232K | Buy |
31,829
+1,289
| +4% | +$8.72K | ﹤0.01% | 3930 |
|
|
2025
Q2 | $164K | Sell |
30,540
-4,633
| -13% | -$22.5K | ﹤0.01% | 4156 |
|
|
2025
Q1 | $188K | Sell |
35,173
-18,824
| -35% | -$132K | ﹤0.01% | 4241 |
|
|
2024
Q4 | $483K | Buy |
53,997
+19,951
| +59% | +$212K | ﹤0.01% | 3859 |
|
|
2024
Q3 | $375K | Buy |
34,046
+14,010
| +70% | +$156K | ﹤0.01% | 3913 |
|
|
2024
Q2 | $182K | Sell |
20,036
-138,539
| -87% | -$1.35M | ﹤0.01% | 3934 |
|
|
2024
Q1 | $2.23M | Buy |
158,575
+153,835
| +3,245% | +$1.92M | ﹤0.01% | 2355 |
|
|
2023
Q4 | $36.4K | Buy |
4,740
+4,727
| +36,362% | +$26.1K | ﹤0.01% | 4683 |
|
|
2023
Q3 | $97 | Sell |
13
-13,477
| -100% | -$115K | ﹤0.01% | 5416 |
|
|
2023
Q2 | $112K | Buy |
13,490
+4,717
| +54% | +$54.4K | ﹤0.01% | 4189 |
|
|
2023
Q1 | $117K | Buy |
+8,773
| New | +$119K | ﹤0.01% | 3964 |
|
|
2021
Q3 | – | Sell |
-453
| Closed | -$6K | – | 5753 |
|
|
2021
Q2 | $6K | Buy |
453
+213
| +89% | +$2.77K | ﹤0.01% | 5790 |
|
|
2021
Q1 | $4K | Sell |
240
-382
| -61% | -$6.9K | ﹤0.01% | 5928 |
|
|
2020
Q4 | $8K | Buy |
622
+468
| +304% | +$8.34K | ﹤0.01% | 6999 |
|
|
2020
Q3 | $6K | Sell |
154
-249
| -62% | -$9.87K | ﹤0.01% | 6878 |
|
|
2020
Q2 | $16K | Buy |
+403
| New | +$14.4K | ﹤0.01% | 6763 |
|
|
2017
Q1 | – | Sell |
-44
| Closed | -$9K | – | 7176 |
|
|
2016
Q4 | $9K | Buy |
+44
| New | +$10.8K | ﹤0.01% | 6768 |
|
|
2016
Q2 | – | Sell |
-63
| Closed | -$19K | – | 7065 |
|
|
2016
Q1 | $19K | Buy |
+63
| New | +$21.7K | ﹤0.01% | 6559 |
|
|
2015
Q4 | – | Sell |
-26
| Closed | -$13K | – | 7538 |
|
|
2015
Q3 | $13K | Buy |
+26
| New | +$18.6K | ﹤0.01% | 6285 |
|
Citigroup's ATXS Position: Q1 2026 in Review
Citigroup sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 927,342 shares — an estimated $12.1M sold.
Citigroup first reported a position in ATXS in Q3 2015 and held it in 20 quarters. The position peaked at $12.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Citigroup reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 927,342 Astria Therapeutics shares in Q1 2026, an estimated $12.1M.
- Citigroup first reported a position in Astria Therapeutics in Q3 2015 and held it in 20 quarters.
- Citigroup's Astria Therapeutics position peaked at $12.1M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.